Dr. Agarwal's Health Care Limited Share Price & Stock Analysis

Dr. Agarwal's Health Care Limited (NSE: AGARWALEYE, BSE: 544350) is a Chennai, Tamil Nadu-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹17,568 Cr, it ranks #403 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 46 in Hospitals and Healthcare Centers. At ₹549.50 (as of 16 Nov 2026), the share price is 3.9% below its 52-week high of ₹571.90 and 37.0% above its 52-week low of ₹401.00. The share price is up 9.3% over one year and up 8.3% over three months.

Key Metrics

Current Price₹549.50
Market Cap₹17,568 Cr
NSE SymbolAGARWALEYE
BSE Code544350
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Facilities > Hospitals and Healthcare Centers
P/E Ratio131.9
Return on Equity8.31%
Return on Assets4.81%
52-Week Range₹401.00 – ₹571.90
1-Year Price Change+9.3%
3-Month Price Change+8.3%
Beta (1Y)0.23
HeadquartersChennai, Tamil Nadu
Websitewww.dragarwals.co.in

Latest Quarterly Results — Q2 FY27

Revenue₹655 Cr
Net Profit₹57 Cr
Net Margin8.7%
EPS (Basic)₹1.65
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Dr. Agarwal's Health Care Limited Quarterly Revenue and Profit Trend

Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr in Q2 FY27, up 31.4% from ₹499 Cr in Q2 FY26 and up 6.7% from ₹614 Cr in Q1 FY27. It posted a net profit of ₹57 Cr for the quarter, against a net profit of ₹36 Cr in Q2 FY26 (up 55.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹460 Cr (Q4 FY25) to ₹655 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹655 Cr₹57 Cr8.7%
Q1 FY27₹614 Cr₹55 Cr9.0%
Q4 FY26₹564 Cr₹50 Cr8.9%
Q3 FY26₹530 Cr₹44 Cr8.2%
Q2 FY26₹499 Cr₹36 Cr7.3%
Q1 FY26₹487 Cr₹38 Cr7.8%
Q4 FY25₹460 Cr₹43 Cr9.2%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 32.33% of Dr. Agarwal's Health Care Limited's shares as of Sept 2026, against 32.42% in Sept 2025 (−0.09 percentage points). Delivery averaged 52.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Dr. Agarwal's Health Care Limited

Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.

Products and Services

1. Eye Care Related Sales and Services-This segment provides a range of eye care services, including cataract, refractive, and other surgeries; and consultation, diagnosis, and non-surgical treatment services. It also sells optical, contact lenses and accessories, and eye care related pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Eye Care Related Sales and Services-100%

Dr. Agarwal's Health Care Limited vs Peers — Hospitals and Healthcare Centers

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Apollo Hospitals Enterprise Limited₹1,23,712 Cr6321.50%₹7,615 Cr+11.6%
Max Healthcare Institute Ltd₹91,978 Cr63.914.33%₹2,569 Cr-16.6%
Manipal Health Enterprises Ltd₹89,110 Cr88.4—₹3,399 Cr—
Aster Dm Healthcare Limited (Asterdm)₹63,041 Cr97.610.07%₹2,829 Cr+4.3%
Fortis Healthcare Ltd.₹58,283 Cr55.111.01%₹2,735 Cr-25.1%
Global Health Ltd (Medanta)₹38,422 Cr69.715.03%₹1,469 Cr+16.2%
Narayana Hrudayalaya Limited₹37,907 Cr46.219.85%₹2,844 Cr+2.8%
Krishna Institute Of Medical Science (KIMS)₹29,056 Cr120.69.72%₹1,344 Cr+0.2%
Dr. Agarwal's Health Care Limited₹17,568 Cr131.98.31%₹655 Cr+9.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Dr. Agarwal's Health Care Limited?

Dr. Agarwal's Health Care Limited is trading at ₹549.50, with a market capitalisation of ₹17,568 Cr.

Which sector does Dr. Agarwal's Health Care Limited belong to?

Dr. Agarwal's Health Care Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).

What are the key financial ratios of Dr. Agarwal's Health Care Limited?

Dr. Agarwal's Health Care Limited has a P/E of 131.9 and a return on equity of 8.31%.

What is the stock symbol of Dr. Agarwal's Health Care Limited?

Dr. Agarwal's Health Care Limited is listed on the NSE under the symbol AGARWALEYE and on the BSE under the scrip code 544350.

How has Dr. Agarwal's Health Care Limited's share price moved over the past year?

Dr. Agarwal's Health Care Limited's share price is up 9.3% over one year and up 8.3% over three months. Its 52-week range is ₹401.00 to ₹571.90.

What were Dr. Agarwal's Health Care Limited's latest quarterly results?

In Q2 FY27, Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr and net profit of ₹57 Cr, with basic EPS of ₹1.65 (consolidated, parsed from the company's exchange filing).

How have Dr. Agarwal's Health Care Limited's revenue and profit changed over the past year?

Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr in Q2 FY27, up 31.4% from ₹499 Cr in Q2 FY26 and up 6.7% from ₹614 Cr in Q1 FY27.

What is the promoter holding in Dr. Agarwal's Health Care Limited?

Promoters held 32.33% of Dr. Agarwal's Health Care Limited's shares as of Sept 2026, against 32.42% in Sept 2025 (−0.09 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.